Valion Bio (VBIO) Accounts Payables (2021 - 2026)

Valion Bio has reported Accounts Payables for 6 years, with the latest figure at $639000.0 in Q2 2026.

• On a quarterly basis, Accounts Payables rose 173.08% year-over-year to $639000.0 in Q2 2026; TTM through Jun 2026 was $639000.0, a 173.08% increase from a year earlier, with the FY2025 full-year figure at $264000.0, up 111.2% from the prior year.
• Accounts Payables was $639000.0 for Q2 2026 at Valion Bio, up from $264000.0 in the prior quarter.
• The five-year high for Accounts Payables was $1.9 million in Q2 2022, with the low at $125000.0 in Q4 2024.
• Average Accounts Payables over 5 years is $719529.4, with a median of $625000.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Accounts Payables slumped 82.47% in 2024, then jumped 173.08% in 2026.
• Over 5 years, Accounts Payables stood at $1.3 million in 2022, then sank by 46.11% to $713000.0 in 2023, then plunged by 82.47% to $125000.0 in 2024, then soared by 111.2% to $264000.0 in 2025, then soared by 142.05% to $639000.0 in 2026.
• The last three Accounts Payables figures came in at $639000.0 (Q2 2026), $264000.0 (Q4 2025), and $465000.0 (Q3 2025), per Business Quant data.